Medtronic Secures CE Mark for Advanced Vessel-Sealing Robot

Medtronic announced on October 3, 2023, that it has received the CE mark in Europe for its innovative LigaSure vessel-sealing technology, designed for use in robotic-assisted surgeries. This certification enhances the capabilities of Medtronic’s Hugo soft tissue robotic system, which is utilized in gynecologic, general, and urologic procedures across Europe.

The Hugo system is not available in the United States yet, but Medtronic anticipates launching it in the U.S. market later in its current fiscal year, which concludes in April 2026. The initial focus for the U.S. launch will be in urology.

Expanding Robotic Surgery Capabilities

The CE mark for LigaSure is a significant step for Medtronic as it aims to strengthen its position in the rapidly growing robotic surgery market, currently dominated by Intuitive Surgical. The expansion of the Hugo platform is central to Medtronic’s strategy for enhancing growth within its surgical business. During the company’s fourth-quarter earnings call in May, CEO Geoff Martha emphasized the importance of LigaSure’s adoption among surgeons, noting its success in gaining market share within the advanced energy segment.

The LigaSure device is designed to seal blood vessels efficiently, achieving this in approximately two seconds while minimizing thermal energy transfer to adjacent tissues. According to Miguel Caceres from the Pacifica Salud Hospital in Panama, “LigaSure technology is one of the most important advances for minimally invasive surgery because it provides sealing and cutting in a way that is very, very secure for the performance of the surgeon and the security of the patient.” Caceres highlighted the confidence that robotic surgeons have in LigaSure’s sealing capabilities.

A Broader Vision for the Future

The Hugo system first received the CE mark in Europe back in 2021 and is currently in operation in over 30 countries. Medtronic has submitted an application to the Food and Drug Administration (FDA) for a urology indication for Hugo in the first quarter of 2023, with plans for future expansions into hernia and gynecologic procedures.

In addition to the CE mark announcement, Medtronic plans to conduct a live telesurgery demonstration utilizing the Hugo system. The company is also set to present new gynecologic data at the Society of Robotic Surgeons Annual Meeting, taking place in Strasbourg, France.

This latest development reflects Medtronic’s commitment to advancing surgical technology and improving patient outcomes through innovative solutions in robotic-assisted surgery.